Sean M Devlin
Overview
Explore the profile of Sean M Devlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
6998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn J, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39893244
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-cell lymphoma (LBCL). This study compares patterns of disease relapse and progression across...
2.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
J Clin Oncol
. 2025 Jan;
:JCO2402424.
PMID: 39883889
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that...
3.
Heller G, Devlin S
J R Stat Soc Ser C Appl Stat
. 2025 Jan;
74(1):83-99.
PMID: 39807176
Survival is poor for patients with metastatic cancer, and it is vital to examine new biomarkers that can improve patient prognostication and identify those who would benefit from more aggressive...
4.
Fein J, McAuliffe A, Fischer K, Brady O, Devlin S, Willumsen S, et al.
Leuk Lymphoma
. 2024 Dec;
:1-8.
PMID: 39641218
Access to allogeneic and autologous hematopoietic stem cell transplantation (SCT) remains inadequate despite its curative potential across hematologic malignancies. In 2015, Hartford HealthCare (HHC) and the Memorial Sloan Kettering Cancer...
5.
Jurgens E, Firestone R, Chaudhari J, Hosszu K, Devlin S, Shah U, et al.
J Clin Oncol
. 2024 Dec;
43(5):498-504.
PMID: 39631041
MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical...
6.
Landgren O, Devlin S
Blood Cancer Discov
. 2024 Dec;
6(1):13-22.
PMID: 39630969
The acceptance of MRD-negative complete response as an endpoint that is reasonably likely to predict clinical benefit will allow for the design of streamlined clinical trials for accelerated approval, enabling...
7.
Boardman A, Gutgarts V, Flynn J, Devlin S, Goldman A, Tomas A, et al.
Haematologica
. 2024 Nov;
110(3):651-664.
PMID: 39568416
Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatment-related toxicity. Cytokine release syndrome and...
8.
Lorenc R, Shouval R, Flynn J, Devlin S, Saldia A, Luna de Abia A, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):990-1000.
PMID: 38972512
Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T...
9.
Benjamini O, Fried S, Shouval R, Flynn J, Beyar-Katz O, Leslie L, et al.
Haematologica
. 2024 Jun;
109(11):3566-3577.
PMID: 38899351
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a...
10.
Cederquist G, Schefflein J, Devlin S, Shah G, Shouval R, Hubbeling H, et al.
Blood Adv
. 2024 Jun;
8(19):5192-5199.
PMID: 38861344
Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable. Bridging radiotherapy (BRT) is used for extracranial...